Canada Managing Common Illness Consumer Report 2026
The OTC category remains robust post-pandemic, even as 6.5% unemployment places many Canadians in cost-conscious mode.
The OTC category remains robust post-pandemic, even as 6.5% unemployment places many Canadians in cost-conscious mode.
"Canadians are becoming more proactive about their overall health. To meet this changing mindset, products that offer effective symptom relief, good value, and strong safety assurances will resonate most.
Meghan Ross, Senior Research Analyst - Home & Beauty
The OTC category remains robust post-pandemic, even as 6.5% unemployment places many Canadians in cost-conscious mode. Canadians are comfortable managing symptoms, with 64% turning to OTC medication to manage common illnesses. Consumers are navigating prolonged symptom seasons, with economic uncertainty and environmental changes converging to drive both higher demand and budget sensitivity. Industry dynamics are shifting due to Health Canada’s NPD Action Plan, which lowers regulatory barriers and accelerates launches, intensifying category competition and rewarding brands that move swiftly with relevant innovation. Regulatory simplification, combined with the extended duration of cold, flu and allergy seasons, opens doors for nimble companies, but also heightens competitive pressure.
The greatest opportunity for brands lies in delivering affordable multi-symptom and immunity-boosting OTC solutions, a response to consumer appetite for prevention and value. Conversely, the most significant threat stems from persistent vaccine hesitancy and rampant misinformation, which risk elevating illness incidence and straining already taxed healthcare systems. Winning brands will proactively address prevention, support public health education, and adapt technology supports quickly to build consumer trust.
This Report covers remedies that can be purchased over-the-counter without a prescription to relieve symptoms of colds, flu, allergies, sore throat, coughs and congestion.